Nicola Chessum

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignee: Cancer Research Technology Limited. Active years: 2017-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicola Chessum. Retrieved from https://idiyas.com/inventor/nicola-chessum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 14(Granted Patents)

Location History:

Sutton, GB (2017)
Sutton Coldfield, GB (2019 - 2023)

Company Filing History:

5 out of 268

Cancer Research Technology Limited

patents

Years Active: 2017-2023

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11787786 - Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 (2023-10-17),

2. 11124501 - Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I (2021-09-21),

3. 10647678 - Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity (2020-05-12),

4. 10189821 - Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I (2019-01-29),

5. 9701664 - Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 (2017-07-11),

Title: Nicola Chessum: Innovator in Cancer Research

Introduction

Nicola Chessum is a prominent inventor based in Sutton Coldfield, GB. She has made significant contributions to the field of cancer research, holding a total of 5 patents. Her work focuses on developing innovative therapeutic agents aimed at combating proliferative diseases, particularly cancer.

Latest Patents

Among her latest patents are the "Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1." This invention relates to compounds that serve as inhibitors of heat shock factor 1 (HSF1). The compounds are designed for use as therapeutic agents in the treatment and prevention of proliferative diseases, such as cancer. Additionally, the patent outlines processes for the preparation of these compounds and pharmaceutical compositions that include them.

Career Highlights

Nicola Chessum is currently associated with Cancer Research Technology Limited, where she continues to advance her research and innovations. Her work has been instrumental in developing new strategies for cancer treatment, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Nicola has collaborated with notable colleagues, including Keith Jones and Matthew D Cheeseman. These partnerships have further enriched her research and contributed to the success of her inventions.

Conclusion

Nicola Chessum stands out as a key figure in cancer research, with her innovative patents paving the way for new therapeutic approaches. Her contributions are vital in the ongoing fight against cancer, and her work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.